22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The following is a summary of key decisions from the National Labor Relations Board (Board) and its ...
Read More >
COVID-19 has affected the way in which companies are conducting their business now and for the fores...
Read More >
On April 18, the Minister of Innovation, Science and Industry issued a policy statement announcing t...
Read More >
Adjustments to the reporting thresholds under the Hart-Scott-Rodino Antitrust Improvements Act of 19...
Read More >
As a result of developments relating to the COVID-19 coronavirus pandemic, the Premerger Notificatio...
Read More >
Corporate - Japanese Government Issues M&A Guidelines - On June 28, 2019, Japan's Ministry of Ec...
Read More >